Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B

Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B

Background/Aims The immune-tolerant (IT) phase of chronic hepatitis B (CHB) patients is not generally indicative of antiviral therapy (AVT). We assessed and compared the risk of hepatocellular carcinoma (HCC) during the IT-phase stringently defined by a low fibrosis-4 (FIB-4) index, compared to that...

Full description

Bibliographic Details
Main Authors: Mi Young Jeon, Beom Kyung Kim, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Seung Up Kim
Format: Article
Language:English
Published: Korean Association for the Study of the Liver 2021-04-01
Series:Clinical and Molecular Hepatology
Subjects:
immune tolerance
antiviral agent
hepatitis b
carcinoma, hepatocellular
hepatic fibrosis
Online Access:http://e-cmh.org/upload/pdf/cmh-2020-0216.pdf

Internet

http://e-cmh.org/upload/pdf/cmh-2020-0216.pdf

Similar Items